ethyl (4-isopropylphenoxy)acetate | 184878-99-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl (4-isopropylphenoxy)acetate
• 英文别名: Ethyl-(4-isopropylphenoxy)acetate；ethyl 2-(4-propan-2-ylphenoxy)acetate
• CAS: 184878-99-7
• 化学式: C₁₃H₁₈O₃
• mdl: MFCD11174654
• 分子量: 222.284
• InChiKey: VYWXFDLFNURGLZ-UHFFFAOYSA-N

物化性质

• 沸点：
  298.1±23.0 °C(Predicted)
• 密度：
  1.026±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl (4-isopropylphenoxy)acetate 在 盐酸 、 正丁基锂 、 N-环己基异丙基胺 、 溶剂黄146 作用下， 反应 0.33h， 生成 Ethyl 2-[2-(chloromethyl)-4-propan-2-ylphenoxy]-3-(4-chlorophenyl)propanoate
  参考文献：
  名称：

  Glucose Transport-Enhancing and Hypoglycemic Activity of 2-Methyl-2-phenoxy-3-phenylpropanoic Acids

  摘要：

  A series of 2-phenoxy-3-phenylpropanoic acids has been prepared which contains many potent hypoglycemic agents as demonstrated by assessing glucose lowering in ob/ob mice. Some compounds (32, 33, 59) normalize plasma glucose in this diabetic model at doses of approximately 1 mg/kg. The mechanism of action of these drugs may involve enhanced glucose transport, especially in fat cells, but the compounds do not stimulate GLUT4 translocation and do not increase the levels of GLUT1 or GLUT4 in vivo. Thus, these compounds may enhance the intrinsic activity of the glucose transporter GLUT1 or GLUT4. Some compounds also modestly decrease hepatocyte gluconeogenesis in vitro, but this is not likely to be a major contributor to the hypoglycemic effect observed in vivo. Likewise, a modest decrease in food consumption observed with some of these compounds was shown by a pair-feeding experiment not to be the primary cause of the hypoglycemia observed.

  DOI：

  10.1021/jm950364f
• 作为产物：
  描述：

  4-异丙基苯酚 、 氯乙酸乙酯 在 sodium hydride 作用下， 生成 ethyl (4-isopropylphenoxy)acetate
  参考文献：
  名称：

  Glucose Transport-Enhancing and Hypoglycemic Activity of 2-Methyl-2-phenoxy-3-phenylpropanoic Acids

  摘要：

  A series of 2-phenoxy-3-phenylpropanoic acids has been prepared which contains many potent hypoglycemic agents as demonstrated by assessing glucose lowering in ob/ob mice. Some compounds (32, 33, 59) normalize plasma glucose in this diabetic model at doses of approximately 1 mg/kg. The mechanism of action of these drugs may involve enhanced glucose transport, especially in fat cells, but the compounds do not stimulate GLUT4 translocation and do not increase the levels of GLUT1 or GLUT4 in vivo. Thus, these compounds may enhance the intrinsic activity of the glucose transporter GLUT1 or GLUT4. Some compounds also modestly decrease hepatocyte gluconeogenesis in vitro, but this is not likely to be a major contributor to the hypoglycemic effect observed in vivo. Likewise, a modest decrease in food consumption observed with some of these compounds was shown by a pair-feeding experiment not to be the primary cause of the hypoglycemia observed.

  DOI：

  10.1021/jm950364f

文献信息

• Sirtuin polymorphisms and methods of use thereof
  申请人：Laakso Markku

  公开号：US20080249103A1

  公开（公告）日：2008-10-09

  Provided herein are methods for diagnosis and prognosis using polymorphic variants of sirtuins. Such polymorphic may be used, for example, to identify subjects that would be responsive to treatment with a sirtuin modulating compound and/or subjects that are suffering from or susceptible to a disease mediated by a sirtuin. Also provided are methods for determining the predictive value of a sirtuin polymorphic variant, methods for evaluating sirtuin modulating compounds, and methods for determining appropriate dosage and/or treatment regimens for subjects having one or more sirtuin polymorphic variants. Screening methods for identifying sirtuin modulating compounds using polymorphic variants of a sirtuin are also provided.

  本文提供了使用sirtuins的多态性变体进行诊断和预后的方法。这种多态性可能被用来识别对sirtuin调节化合物治疗有响应的受试者，以及患有或易受sirtuin介导疾病影响的受试者。还提供了确定sirtuin多态性变体预测价值的方法，评估sirtuin调节化合物的方法，以及确定具有一个或多个sirtuin多态性变体的受试者的适当剂量和/或治疗方案的方法。还提供了使用sirtuin的多态性变体筛选识别sirtuin调节化合物的筛选方法。
• PPAR activators
  申请人：Pfizer Inc

  公开号：US20040157885A1

  公开（公告）日：2004-08-12

  PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.

  PPAR alpha激动剂，含有这些化合物的药物组合物以及使用这些化合物提高某些血浆脂质水平，包括高密度脂蛋白胆固醇并降低其他某些血浆脂质水平，例如低密度脂蛋白胆固醇和甘油三酯，并因此治疗由低HDL胆固醇水平和/或高LDL胆固醇和甘油三酯水平加重的疾病，如动脉粥样硬化和心血管疾病，在哺乳动物中，包括人类。
• Sirtuin modulating compounds
  申请人：Nunes J. Joseph

  公开号：US20070037809A1

  公开（公告）日：2007-02-15

  Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了新型的sirtuin调节化合物及其使用方法。这些sirtuin调节化合物可用于增加细胞寿命，并治疗和/或预防各种疾病和疾病，包括与衰老或应激有关的疾病或疾病，糖尿病，肥胖症，神经退行性疾病，心血管疾病，血液凝块性疾病，炎症，癌症和/或红斑病，以及需要增加线粒体活性的疾病或疾病。还提供了包含sirtuin调节化合物和另一种治疗剂的组合物。
• PPAR ACTIVATORS
  申请人：Bagley W. Scott

  公开号：US20070191429A1

  公开（公告）日：2007-08-16

  PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.

  PPAR alpha激动剂，含有这种化合物的制药组合物以及使用这种化合物提高某些血浆脂质水平，包括高密度脂蛋白胆固醇和降低某些其他血浆脂质水平，如低密度脂蛋白胆固醇和三酰甘油，因此治疗低密度脂蛋白胆固醇和/或高三酰甘油水平加重的疾病，例如动脉粥样硬化和心血管疾病，在哺乳动物，包括人类中使用。
• Piperidine compounds useful as PPAR activators
  申请人：Pfizer Inc.

  公开号：US07199243B2

  公开（公告）日：2007-04-03

  PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.

  PPARα激动剂、含有该化合物的药物组合物以及使用该化合物提高某些血浆脂质水平（包括高密度脂蛋白胆固醇）和降低某些其他血浆脂质水平（如低密度脂蛋白胆固醇和甘油三酯），并因此治疗由低HDL胆固醇水平和/或高LDL胆固醇和甘油三酯水平加重的疾病，例如动脉粥样硬化和心血管疾病，适用于哺乳动物，包括人类。